791 related articles for article (PubMed ID: 27135278)
1. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
3. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
4. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
[TBL] [Abstract][Full Text] [Related]
5. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
[TBL] [Abstract][Full Text] [Related]
7. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
[TBL] [Abstract][Full Text] [Related]
8. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
9. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.
Guerra CR; Ishida K; Nucci M; Rozental S
Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):582-90. PubMed ID: 22850947
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil.
Herkert PF; Meis JF; Lucca de Oliveira Salvador G; Rodrigues Gomes R; Aparecida Vicente V; Dominguez Muro M; Lameira Pinheiro R; Lopes Colombo A; Vargas Schwarzbold A; Sakuma de Oliveira C; Simão Ferreira M; Queiroz-Telles F; Hagen F
J Med Microbiol; 2018 Apr; 67(4):560-569. PubMed ID: 29461182
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
13. Diversity and Antifungal Drug Susceptibility of Cryptococcus Isolates in Thailand.
Worasilchai N; Tangwattanachuleeporn M; Meesilpavikkai K; Folba C; Kangogo M; Groß U; Weig M; Bader O; Chindamporn A
Med Mycol; 2017 Aug; 55(6):680-685. PubMed ID: 27915307
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
15. [Genotypes and in vitro antifungal susceptibility of Cryptococcus isolates in Sichuan Province].
Lei Y; Xiao YL; He C; Zhang CY; Xie Y; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jan; 46(1):82-6. PubMed ID: 25807801
[TBL] [Abstract][Full Text] [Related]
16. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
Liaw SJ; Wu HC; Hsueh PR
Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Kassi FK; Drakulovski P; Bellet V; Roger F; Chabrol A; Krasteva D; Doumbia A; Landman R; Kakou A; Reynes J; Delaporte E; Menan HEI; Bertout S
PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007812. PubMed ID: 31738768
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
